Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/29 22:59:29」(JST)

wiki en

Risedronic acid (INN) often used as its sodium salt risedronate sodium (USAN) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.

Controversies

In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.^[1] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".^[2]

In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports^[3] and discussion).^[4]

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.

References

^ "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.
^ NY fed judge finds promotions for bone drug Boniva are fair Associated Press, 7 Sept 2006^{[dead link]}
^ http://www.thejabberwock.org/wiki/index.php?title=Actonel_Case_Media_Reports
^ "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.

External links

Actonel adverse events reported to the FDA
Risedronic acid bound to proteins in the PDB

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 閉経後女性における骨粗鬆症に対するビスホスホネート投与 the use of bisphosphonates in postmenopausal women with osteoporosis
2. ステロイド誘発性骨粗鬆症の予防および治療 prevention and treatment of glucocorticoid induced osteoporosis
3. アロマターゼ阻害剤による骨量減少の評価およびマネージメント evaluation and management of aromatase inhibitor induced bone loss
4. ビスホスホネートの薬理学 pharmacology of bisphosphonates
5. 骨パジェット病の治療 treatment of paget disease of bone

English Journal

Risedronate as an intra-abdominal sepsis mimic: a case report.

Shah S1, Jeremiah C, Johnson D, Baker S.
Archives of osteoporosis.Arch Osteoporos.2015 Dec;10(1):213. doi: 10.1007/s11657-015-0213-8. Epub 2015 Mar 20.
This case report highlights the potential severity of bisphosphonate-associated reactions.CASE REPORT: A 76-year-old lady underwent several hospital admissions for investigation of fever associated with rigors, abdominal pain, and vomiting.DISCUSSION: Despite multiple investigations, no cause was fo
PMID 25792348

Effects of swimming associated with risedronate in osteopenic bones: An experimental study with ovariectomized rats.

Paliologo T1, Shimano RC2, Shimano AC3, Macedo AP4, Falcai MJ5, Issa JP6.
Micron (Oxford, England : 1993).Micron.2015 Nov;78:40-4. doi: 10.1016/j.micron.2015.07.002. Epub 2015 Jul 10.
Physical activity and risedronate sodium have effects on metabolic bone diseases, maintaining the integrity of bone tissue. Our objective was to evaluate the effects of swimming associated with risedronate as a prophylactic means in osteopenic bone of ovariectomized rats. A total of 24 animals of th
PMID 26210684

On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method.

Yang Y1, Liu C1, Zhang Y1, Zhou L1, Zhong D1, Chen X2.
Journal of pharmaceutical and biomedical analysis.J Pharm Biomed Anal.2015 Oct 10;114:408-15. doi: 10.1016/j.jpba.2015.05.038. Epub 2015 Jun 18.
Minodronic acid (MA) is a third-generation bisphosphonate (BP). Its high potency allows lower doses to be administered in clinical settings compared with other BPs, which results in extremely low systemic exposure. Therefore, it is essential to develop an ultra-sensitive bioassay for pharmacokinetic
PMID 26117452

Japanese Journal

Industrial Info. リセドロネート(アクトネル)の骨折予防効果 : 大腿骨近位部骨折予防効果を中心に

鈴木良則
細胞 44(7), 299-302, 2012-06-00
NAID 40019385779

リセドロネート低反応性の多骨型 Paget 病の1例

正本和誉,大浦好一郎,坂口雅彦,富原光雄
中部日本整形外科災害外科学会雑誌. 中部日本整形外科災害外科学会抄録 55(3), 533-534, 2012-05-01
NAID 10030775672

Related Pictures

risedronate oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD Risofos (Risedronate Sodium) - United Pharmacies Risedronate sodium Tablets - Risedronate sodium Tablets Manufacturer & Supplier,Exporter Risedronate | Sun Pharmaceutical Industries Ltd. Buy Actonel, Purchase Risedronate Sodium used to prevent and treat osteoporosis Risedronate Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD Risofos (Risedronate Sodium) - United Pharmacies RSN 5 mg Pill Images (Yellow / Elliptical / Oval)

★リンクテーブル★

リンク元	「ビスホスフォネート」「リセドロン酸」「risedronic acid」
拡張検索	「sodium risedronate hydrate」

「ビスホスフォネート」

Risedronic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: B3; US: C (Risk not ruled out); ;
Routes of; administration	Oral
ATC code	M05BA07 (WHO);
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	0.63%
Protein binding	~24%
Metabolism	None
Biological half-life	1.5 h
Excretion	Renal and fecal
Identifiers
	IUPAC name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid;
CAS Number	105462-24-6 ;
PubChem CID	5245;
IUPHAR/BPS	3176;
DrugBank	DB00884 ;
ChemSpider	5055 ;
UNII	KM2Z91756Z;
ChEMBL	CHEMBL923 ;
ECHA InfoCard	100.116.436
Chemical and physical data
Formula	C7H11NO7P2
Molar mass	283.112 g/mol
3D model (JSmol)	Interactive image;
	SMILES OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O ;
	InChI InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15) ; Key:IIDJRNMFWXDHID-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: bisphosphonate
同: ビスフォスフォネート、ビスホスホネート、ビスホスホン酸、ビスホスホネート製剤
関: 骨粗鬆症

第1世代

エチドロネート etidronate

第2世代

第3世代

「リセドロン酸」

　　[★]

英: risedronate risedronic acid
般: リセドロン酸ナトリウム水和物 sodium risedronate hydrate
商: アクトネル、ベネット
同: リセドロネート
関: 骨粗鬆症

添付文書

ベネット錠17.5mg

http://www.info.pmda.go.jp/go/pack/3999019F2030_1_06/3999019F2030_1_06?view=body

-ベネット

「risedronic acid」

　　[★]

リセドロン酸

関: risedronate、sodium risedronate hydrate

「sodium risedronate hydrate」

　　[★]

リセドロン酸ナトリウム水和物

関: risedronate、risedronic acid

[1] "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.

[2] NY fed judge finds promotions for bone drug Boniva are fair Associated Press, 7 Sept 2006^{[dead link]}

[3] ttp://www.thejabberwock.org/wiki/index.php?title=Actonel_Case_Media_Reports

[4] "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.

v t e Drugs for treatment of bone diseases (M05)
Bisphosphonates	Nitrogenous (Alendronic acid ibandronic acid incadronic acid pamidronic acid risedronic acid zoledronic acid) Non-nitrogenous (Etidronic acid clodronic acid tiludronic acid)
Bone morphogenetic proteins	Dibotermin alfa Eptotermin alfa
Other	Resorption inhibitor (Ipriflavone) Aluminium chlorohydrate Dual action bone agent (Strontium ranelate) RANKL inhibitor (Denosumab) Cathepsin K inhibitor (Odanacatib) Calcium Vitamin D

匿名

検索

案内

案内

risedronate